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Methods: Telomere, cognitive, and CSF data from 482 participants in the AD Neuroimaging Initia-
tive (148 cognitively normal, 283 mild cognitive impairment, 51 AD) was leveraged to assess telo-
mere length associations with cognition (measured by memory and executive function) and
interactions with CSF amyloid-b, tau, and APOE-ε4. Secondary analyses assessed brain volume
and thickness outcomes.
Results: Longer telomeres at baselinewere associated with faster executive function decline. Amyloid-b
and tau interacted with telomere length on cognition, with longer telomeres related to faster decline
among biomarker-positive individuals.
Discussion: Telomere associations with cognition shift with AD progression, with longer telomeres
related to worse outcomes as pathology increases, highlighting the need for further investigation of
telomere length along the AD neuropathological cascade.
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Telomeres are long, repeated sequences at the end of
chromosomes [1], which typically shorten with each cell
cycle due to incomplete replication, leading to cellular
senescence or cell death [2]. Telomeres serve to prevent
genomic instability and chromosome fusion and shortened
telomere length is unsurprisingly associated with many
age-related diseases [3]. For this reason, telomere length
has been leveraged in previous work as a marker of biolog-
ical aging, a process that may be distinct from chronologicalimer’s Association. This is an open access article under the CC BY-NC-ND
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senescence and death, it is expected that they would also pro-
tect neuronal cells from the oxidative stress and neurodegen-
eration that are part of the progression of Alzheimer’s
disease (AD). However, reports of the role of telomere
length in AD risk are mixed. Though some studies have
observed no association between telomere length and AD
[5,6], other studies have found shorter telomeres in partici-
pants with AD [7–10] or other types of dementia [11]
compared to cognitively normal participants. In contrast,
Thomas et al. [7] observed longer telomere length in the hip-
pocampus of individuals who had AD compared to controls.
However, these associations varied by age as well as by the
cell type and tissue type in which telomere length was
measured even within the same study.
In addition to dementia, telomere length has been associ-
ated with cognition and AD severity in several studies
[8,12,13], although the literature again is not consistent
[5,14–16]. Interestingly, one study found a nonlinear
association between telomere length and mild cognitive
impairment (MCI), where both the shortest and longest
telomere-length quintiles were associated with increased
risk of amnestic MCI [17]. In a separate study, individuals
with MCI who progressed to AD had longer telomeres
than those with stable MCI [18]. Together, these findings
suggest that the association between telomere length and
cognition is complex and may change over the clinical
course of the disease.
Our previous work has identified genes involved in telo-
mere maintenance that modify the association between AD
biomarkers and downstream neurodegeneration [19,20],
highlighting a potential pathway of neuroprotection from
the consequences of AD pathology. Specifically, in agnostic
scans for genetic variants that modify the association be-
tween cerebrospinal fluid (CSF) levels of amyloid-b (Ab)
or tau and neurodegeneration, we identified variants in the
protection of telomeres 1 (POT1) gene [20] and the serine
palmitoyltransferase long chain base subunit 1 (SPTLC1)
gene [19], which regulate telomerase through ceramide syn-
thesis. These associations suggest that telomeres may be
particularly relevant to the neurodegenerative response to
AD pathology.
Few studies investigating telomere length in the context
of AD have assessed associations or interactions with bio-
markers of AD pathology [10,18,21]. To date, two studies
have observed no association between telomere length and
Ab burden at autopsy or in the CSF [10,18]. Interestingly,
Rolyan et al. [21] found that an ADmouse model with short-
ened telomeres had reduced Ab pathology and less cognitive
impairment compared to AD mice with normal telomeres.
More work in larger cohorts assessing interactions between
biomarkers of AD neuropathology and telomere length may
clarify whether telomere length is relevant to the down-
stream consequences of neuropathology.
Additionally, APOE-ε4 allele status, a major risk factor
for AD, may contribute to the heterogeneity in the associa-tion between telomeres and cognition. Wikgren et al. [22]
observed that nondemented APOE-ε4 carriers had longer
telomeres and a faster rate of attrition compared to noncar-
riers. Furthermore, longer telomeres were predictive of
worse cognitive performance in those APOE-ε4 carriers.
The differences in telomere length and rate of shortening
between APOE-ε4 carriers and noncarriers is one that bears
further study, particularly in the context of AD-related out-
comes.
The goal of this project was to assess the association
between baseline leukocyte telomere length and cognitive
performance, as well as the interaction between biomarkers
of AD neuropathology and leukocyte telomere length on
cognitive trajectories. Additionally, we examined telomere
associations with and biomarker interactions on brain vol-
ume outcomes. The outcome of this work will clarify the de-
gree to which baseline telomere length provides protection
or susceptibility to the consequences of AD neuropathology.2. Materials and methods
2.1. Participants
Data were acquired from the AD Neuroimaging Initiative
(ADNI), a longitudinal, multisite study launched as a public-
private partnership in 2004 led by Principal Investigator
Michael W. Weiner, MD. Recruited participants were
55–90 years old and had no significant neuropathological
disease, except for AD, and did not have a history of brain
lesion, head trauma, or psychoactive medication use. See
http://adni.loni.usc.edu/about/ for more details about the
ADNI study. For the current analyses, we leveraged data
from participants who had baseline telomere length mea-
surement and CSF biomarker acquisition within one year
of each other, as well as longitudinal cognition. These
criteria left 482 participants for the main analyses. For sec-
ondary analyses, we restricted the sample to participants
with longitudinal magnetic resonance imaging data, drop-
ping the sample size to 440. Informed consent was obtained
from all participants or an authorized representative.
Longitudinal collection of cognitive, imaging, and CSF data
began before telomere lengthmeasurement. Cognitive or imag-
ing visits more than 180 days before telomere measurement
were dropped and the closest visit to telomere measurement
was considered baseline for the current analyses. Additionally,
any participant who did not have CSF acquisition within one
year of telomere measurement was excluded.
2.2. Measurement of telomere length
Genomic DNA from ADNI subjects was extracted from
buffy coats or blood at the National Centralized Repository
for Alzheimer’s Disease and Related Dementias (NCRAD).
NCRAD technicians then plated and shipped genomic DNA
to the Telomere Biology Core Lab at the University of Cali-
fornia, San Francisco. Technicians blinded to demographic
and clinical data performed quantitative polymerase chain
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S ratio). The current analyses used T/S ratios adjusted for
experimental variables, which were then converted into base
pairs using the following calculation: telomere base
pairs 5 3274 1 2413 * (T/S ratio). Only baseline telomere
length was used for the current analyses. For more details
on telomere length acquisition and quality control, see the
ADNI telomere methods document on LONI (http://adni.
loni.usc.edu/) and Nudelman et al. [23].
2.3. Cognitive composites
Cognition data was downloaded from the ADNI database
on July 12, 2018. Comprehensive neuropsychological eval-
uations were performed at multiple time points and compos-
ite measures of memory and executive function were
calculated as reported previously [24,25]. Briefly, the mem-
ory composite included item-level data from Rey Auditory
Verbal Learning Test, AD Assessment Scale-Cognitive
Test, Mini-Mental State Examination, and Logical Memory
I and II. The executive function composite included item-
level data from Trail Making Test Parts A and B, Digit
Span Backward, Digit Symbol, Animal Fluency, Vegetable
Fluency, and Clock Drawing Test.
2.4. CSFAD biomarkers
CSF was collected by lumbar puncture. The current ana-
lyses used the closest CSF collection to the baseline telo-
mere measurement. Levels of Ab-42 and total tau (t-tau)
were quantified on the multiplex xMAP Luminex platform
(LuminexCorp,Austin, TX) and Innogenetics INNO-BIAAlz-
Bio3 (Innogenetics, Ghent, Belgium) immunoassay reagents,
as described previously [26]. To interpret results from
biomarker interaction analyses, we stratified the analyses
by biomarker groups, based on previously defined thresholds
of 192 pg/mL for Ab positivity and 93 pg/mL for t-tau
positivity [27].
2.5. Brain volume and cortical thickness outcomes
Brain volume data was collected at multiple time points
as part of ADNI’s comprehensive neuroimaging protocol,
which has been described elsewhere [28]. The current ana-
lyses leveraged volume metrics that we have analyzed in
previous work [29] including the hippocampus, inferior
lateral ventricles (ILV), and thickness measures [29] from
four brain networks that are known to change over the course
of aging and AD: the default mode network, frontal lobe,
medial temporal cortex, and sensory cortex [30].
2.6. Statistical analyses
Statistical analyses were conducted in R (version 3.5.1,
https://www.r-project.org/). Significance was set a priori to
a 5 0.05. P value corrections were performed using the
Bonferroni method for the number of tests in each analysis.We analyzed associations between telomere length and
both cross-sectional and longitudinal cognition (executive
function and memory), as well as interactions between
telomere length and CSF levels of Ab-42 and t-tau on
the cognitive outcomes. Analyses leveraged mixed effects
regression models with the intercept and interval (modeled
as time in years from baseline) entered as both fixed and
random effects. Longitudinal cognitive change was evalu-
ated with an interval-predictor interaction term. Biomarker
interaction models were run with continuous CSF measures
and models stratified by Ab and tau positivity were run to
interpret observed biomarker interaction effects. All
models covaried for sex, age, and diagnosis closest to telo-
mere length acquisition. Secondary analyses were run to
assess interactions with APOE-ε4 allele status as well as
associations with AD biomarker levels and brain volumes.
All brain volume and thickness models covaried for intra-
cranial volume and scanner strength, as well as age, sex,
and baseline diagnosis. Associations with both baseline
volume or thickness and annual change in volume or thick-
ness were evaluated.3. Results
Participant characteristics are presented in Table 1. Par-
ticipants were well-educated and over 50% were MCI. As
expected, diagnostic groups differed in baseline cognitive
performance, AD biomarker levels, and the prevalence of
the APOE-ε4 allele. No group differences in telomere length
were observed. In the imaging subset, baseline brain vol-
umes and thicknesses differed by diagnosis, with MCI and
AD participants having progressively smaller brain volumes
and thickness and larger ILV volumes.3.1. Telomere length associations with cognition
Longer telomeres were associated with faster decline in
executive function (Table 2 and Fig. 1). In interaction
models, tau interacted with telomere length on baseline
executive function and both Ab and tau interacted with telo-
mere length on change in executive function. In stratified
models, longer telomeres were associated with lower base-
line executive function among tau-positive individuals and
with faster decline in executive function in biomarker-
positive individuals (Table 3 and Fig. 2). These associations
and interactions passed correction for multiple tests.
APOE-ε4 allele status also interacted with telomere
length significantly to predict executive function trajectories
(P5 .003; see Fig. 3 and Supplementary Table 1), such that
longer telomeres in ε4 carriers are associated with faster
decline in executive function performance (P 5 .001).
Both associations survived correction for multiple compari-
sons. This association appears to be in a dose-dependent
fashion with the effect appearing strongest among ε4 homo-
zygotes (see Supplementary Fig. 1).
Table 1
Participant characteristics
NC MCI AD P value Total
N 148 283 51 482
Age at baseline, years 75.49 6 6.45 72.22 6 7.41 75.39 6 8.06 ,.01 73.56 6 7.36
Sex, % female 49% 46% 35% .22 46%
% Non-Hispanic white 95% 96% 94% .69 95%
Education, years 16.43 6 2.72 16.15 6 2.61 16.04 6 2.72 .52 16.22 6 2.65
% APOE-ε4 carriers 26% 44% 75% ,.01 42%
Memory performance 1.02 6 0.60 0.28 6 0.72 20.93 6 0.56 ,.01 0.38 6 0.87
Executive function 0.85 6 0.81 0.36 6 0.86 20.92 6 0.89 ,.01 0.38 6 0.98
CSF Ab-42, pg/mL 192.33 6 52.86 172.77 6 50.36 142.79 6 41.23 ,.01 175.61 6 52.18
CSF t-tau, pg/mL 70.22 6 32.43 90.19 6 54.89 126.92 6 55.76 ,.01 87.87 6 51.65
Telomere length, bp 5339.56 6 376.07 5396.59 6 378.89 5434.82 6 419.15 .20 5383.12 6 382.92
Imaging outcomes
N 135 258 47 440
ILV volume, mm3 1337.26 6 962.20 1689.84 6 1272.48 3041.30 6 1531.83 ,.01 1726.02 6 1307.23
Hippocampal volume, mm3 7350.61 6 932.06 7057.93 6 1126.00 5325.72 6 1110.20 ,.01 6962.70 6 1214.52
Default mode network
thickness
55.95 6 2.94 55.91 6 2.99 51.26 6 3.50 ,.01 55.43 6 3.35
Frontal lobe thickness 58.64 6 3.15 58.73 6 2.71 56.35 6 3.57 ,.01 58.45 6 3.03
Medial temporal lobe
thickness
23.45 6 1.63 22.89 6 2.11 20.13 6 2.29 ,.01 22.77 6 2.20
Sensorimotor cortex
thickness
3443.52 6 576.90 3598.44 6 524.87 3496.50 6 545.02 .02 3540.02 6 546.87
Intracranial volume, mm3 1494888.74 6 149356.69 1525088.05 6 153513.36 1510446.81 6 154640.18 .17 1514233.74 6 152630.51
NOTE. Boldface indicates P values less than .05. Values are either mean 6 standard deviation or % of total.
Abbreviations: NC, normal cognition; MCI, mild cognitive impairment; AD, Alzheimer’s disease; APOE, apolipoprotein E; CSF, cerebrospinal fluid; Ab-42,
b-amyloid-42; bp, base pair; ILV, inferior lateral ventricle.
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brain volumes
Telomere length was not associated with CSF levels of
Ab or tau (P . .13). Additionally, telomere length was not
associated with any of the brain volume outcomes, cross-
sectionally or longitudinally (see Supplementary Table 2).
However, there was an interaction between Ab and telomere
length on medial temporal lobe thickness that approached
our corrected threshold for statistical significance
(b 5 2 ! 1026, standard error 5 1 ! 1026, P 5 .005),
such that longer telomeres were associated with greater
decline in medial temporal lobe thickness among biomarker
negative individuals (see Supplementary Table 3 and
Supplementary Fig. 2).Table 2
Telomere length association with cognition
Outcome Model b SE DF P value
Executive
function
longitudinal 27.01E-05 2.14E-05 2042 .0011*
Memory
performance
cross-sectional 21.17E-04 9.01E-05 478 .1937
Memory
performance
longitudinal 21.70E-05 1.69E-05 2066 .3129
Executive
function
cross-sectional 28.09E-05 1.02E-04 477 .4266
NOTE. Boldface indicates P values less than .05. Asterisks indicate
models that survived Bonferroni correction for four tests.
Abbreviations: b, beta; SE, standard error; DF, degrees of freedom.4. Discussion
The present study provides evidence that the downstream
associations of longer baseline telomeres on cognition depends,
in part, on the presence or absence of neuropathology.Fig. 1. Telomere length and longitudinal executive function performance.
Telomere length is associated with longitudinal executive function decline,
shown here with telomere length in base pairs on the x-axis and annual
change in executive function on the y-axis.
Table 3
Telomere length interactions with CSF AD biomarkers on cognition
Outcome Model
b SE DF P value b SE DF P value b SE DF P value
Ab-42 interaction Ab-42 positive Ab-42 negative
Executive
function
longitudinal 1.46E-06 3.99E-07 2035 .0003* 20.0001 3.52E-05 1168 .0006* 5.92E-06 2.12E-05 866 .7799
Memory
performance
longitudinal 5.86E-07 3.04E-07 2059 .0540 23.66E-05 2.59E-05 1189 .1583 2.12E-05 1.62E-05 869 .1903
Executive
function
cross-
sectional
3.10E-06 1.77E-06 474 .0802 26.52E-05 0.0001 294 .6287 4.96E-05 0.0001 178 .7072
Memory
performance
cross-
sectional
2.68E-06 1.58E-06 475 .0908 28.48E-05 0.0001 295 .4768 26.01E-05 0.0001 178 .6283
Tau interaction Tau positive Tau negative
Executive
function
longitudinal 21.79E-06 4.44E-07 1952 5.86E-05* 20.00021 4.86E-05 603 1.46E-05* 22.73E-05 2.14E-05 1348 .2030
Memory
performance
longitudinal 26.38E-07 3.40E-07 1976 .0611 27.34E-05 3.64E-05 616 .0443 6.87E-06 1.71E-05 1359 .6881
Executive
function
cross-
sectional
24.54E-06 1.87E-06 455 .0156 20.00021 0.0002 158 .3152 27.17E-06 0.0001 295 .9480
Memory
performance
cross-
sectional
21.45E-06 1.64E-06 456 .3759 20.00011 0.0002 159 .5303 20.0001 9.57E-05 295 .2853
NOTE. Boldface indicates P values less than .05. Asterisks indicate models that survived Bonferroni correction for eight tests.
Abbreviations: b, beta; SE, standard error; DF, degrees of freedom; Ab-42, b-amyloid-42.
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more rapid cognitive decline in the presence of enhanced bio-
markers of AD neuropathology. In contrast, longer telomeres
among biomarker-negative individuals displayed null or
borderline protective associations with downstream brain ag-
ing outcomes. Together, these results suggest that longer telo-
meres at baseline are associated with worse longitudinal
outcomes among people with high levels of baseline pathol-
ogy, but better longitudinal outcomes among peoplewith lower
levels of baseline pathology. Such complex interactions may
partially explain the heterogeneity in the telomere literature,
as telomere associations appear to change over the course of
the neuropathological cascade in AD.BA
Fig. 2. CSF biomarker interactions with telomere length on longitudinal exec
on change in executive function, such that telomere length is associated with de
change in executive function is presented on the y-axis, and telomere length alon
with biomarker-positive individuals in red and biomarker-negative individuals iOur primary finding was that longer leukocyte telomeres
at baseline were associated with more rapid longitudinal
cognitive decline, particularly among individuals with evi-
dence of greater AD pathology. The direction of this associ-
ation is counterintuitive given that shorter telomeres have
previously been linked to cognitive decline in nondemented,
aging adults as well as a more severe presentation of AD
[8,12,31]. However, another study observed a similar result
whereby longer leukocyte telomeres were associated with
increased risk of conversion to MCI and AD [18]. Moreover,
Liu et al. [32] found that longer peripheral blood cell telo-
meres were associated with worse Minimum Mental State
Examination (MMSE) scores.utive function. Telomere length interacts with both CSF Ab-42 and tau
cline in executive function only in biomarker-positive individuals. Annual
g on the x-axis. Points and lines are colored by CSF amyloid or tau status,
n black.
Fig. 3. APOE-ε4 carrier status x telomere length interaction on executive
function. Telomere length interacts with APOE-ε4 carrier status on change
in executive function, such that longer telomeres at baseline are associated
with decline in executive function among carriers only. Annual change in
executive function is presented on the y-axis, and telomere length on the
x-axis. Points and lines are colored by APOE-ε4 carrier status, with carriers
in red and noncarriers in black.
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explain the detrimental associations of longer telomeres
among biomarker-positive individuals. One possibility is
that telomerase (which maintains telomere length) is upre-
gulated in response to AD pathology and drives a slowing
of telomere shortening during the preclinical phases of
AD. In support of such a possibility, previous work has
demonstrated upregulation of telomerase in response to
inflammation [33] and immune activation [34,35], both
of which occur in response to AD pathology [36]. In
such a scenario telomerase may be actively elongating
and maintaining telomeres in response to the inflammatory
cascade in AD. In opposition to this hypothesis, there is
also evidence that Ab inhibits telomerase activity [37],
suggesting that an upregulation of telomerase’s canonical
activity may be unlikely. However, as intracellular Ab
may decrease with the development of extracellular pla-
ques [38], telomerase could potentially be more active as
the plaques accumulate.
A second possibility is that this detrimental association re-
flects an epiphenomenon due to a non-telomere-related upre-
gulation of telomerase components. For example, the catalytic
subunit of telomerase, TERT, has been shown to protect
against both tau- and amyloid-mediated oxidative stress and
apoptosis in cultured neurons [39,40]. It may be that longer
telomeres reflect an enhanced state of TERT activation that
is beneficial early in disease, but becomes detrimental as
inflammation accelerates. Regardless of the underlying mech-
anisms, a more comprehensive assessment of how telomereassociations change over the course of the neuropathological
cascade in AD is needed.
A comparable interaction was also observed with APOE
status, such that longer telomeres in APOE-ε4 homozygotes
were associated with faster cognitive decline. This corre-
sponds to another study in which longer telomeres were asso-
ciatedwith worse episodic memory performance in ε4 carriers
compared to noncarriers [22]. In contrast, Takata et al. [6]
found that APOE-ε4 homozygotes with AD had shorter telo-
meres than heterozygotes and noncarriers, although they did
not see an association between telomere length and cognitive
decline. The ε4 allele has a proinflammatory effect [41] and a
strong association with AD pathology [42], leaving open the
possibility that either of the mechanisms discussed above
could be driving the APOE interactions observed here.
In contrast to the detrimental associations observed among
biomarker positive individuals, we observed a beneficial effect
of longer telomeres among biomarker individuals, whereby
longer telomeres were associated with a slower rate of cortical
thinning in the medial temporal cortex. Comparable associa-
tions between telomere length and brain volumes have been re-
ported in the past [43], particularly among nondemented
individuals and in subcortical regions of the hippocampus
[43–45]. Since the medial temporal lobe is one of the first to
exhibit atrophy in the beginning stages of AD [46], the current
results suggest that longer telomeres may protect against initial
decline before substantial pathology has accumulated. Given
that we did not see significant associations between telomere
length and brain volume outcomes among biomarker positive
individuals, it is possible that the telomere interaction on cogni-
tion may result from an alternative pathway of injury in AD.
Although neurodegeneration is the primary pathway by which
AD pathology drives cognitive impairment [47], there are also
alternative pathways such as reductions in cerebral blood flow,
white matter degeneration, network connectivity, and glucose
metabolism. More studies are needed to truly understand the
exactmolecular pathways bywhich longer leukocyte telomeres
are associated with worse cognitive outcomes.
This study exhibits multiple strengths including the breadth
of cognitive, imaging, and genetic data available in the cohort,
the detailed measures of telomere length, and the longitudinal
data following telomere measurement. However, the study is
not without limitations. One limitation of the present study
is that telomeres were measured peripherally, which may not
reflect telomeric changes in the brain. Lukens et al. [48] found
that shortened leukocyte telomere length correlated with cere-
bellar telomere length in AD patients, but the correlation
remains an open question in the field. A second limitation is
that the cohort is primarily well-educated, non-Hispanic white
individuals, which limits the ability to generalize the findings
to other populations. Additionally, we were unable to control
for environmental factors like socioeconomic status or life-
style which may impact telomere length [49,50]. Finally, the
current analyses were underpowered to measure interactions
with age or age-stratified models, but that would be an inter-
esting way to assess at what age telomere length is a useful
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will be needed to fully characterize the complex interactions
among age, pathology, and telomeres and how they contribute
to cognitive impairment and dementia.
In conclusion, this study has described a unique interaction
between telomere length and biomarkers of AD neuropa-
thology, suggesting that telomere associations may depend
on the neuropathological context in which they are measured.
Additional work focusing on the complex interplay between
markers of biological aging, chronological aging, and disease
may clarify the context in which telomeres are most relevant
to AD risk and progression.
Acknowledgments
This work was supported by the National Institutes of Health
[R01 AG059716].
Data collection and sharing for this project was funded by
the Alzheimer’s Disease Neuroimaging Initiative (ADNI)
(National Institutes of Health Grant U01 AG024904) and
DOD ADNI (Department of Defense award number
W81XWH-12-2-0012). ADNI is funded by the National Insti-
tute on Aging, the National Institute of Biomedical Imaging
and Bioengineering, and through generous contributions
from the following: AbbVie, Alzheimer’s Association; Alz-
heimer’s Drug Discovery Foundation; Araclon Biotech;
BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company;
CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals,
Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La
Roche Ltd and its affiliated company Genentech, Inc.; Fujire-
bio; GEHealthcare; IXICOLtd.; JanssenAlzheimer Immuno-
therapy Research & Development, LLC.; Johnson & Johnson
Pharmaceutical Research & Development LLC.; Lumosity;
Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics,
LLC.; NeuroRx Research; Neurotrack Technologies; Novartis
Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging;
Servier; Takeda Pharmaceutical Company; and Transition
Therapeutics. The Canadian Institutes of Health Research is
providing funds to support ADNI clinical sites in Canada.
Private sector contributions are facilitated by the Foundation
for the National Institutes of Health (www.fnih.org). The
grantee organization is the Northern California Institute for
Research and Education, and the study is coordinated by the
Alzheimer’s Therapeutic Research Institute at the University
of Southern California. ADNI data are disseminated by the
Laboratory for Neuro Imaging at the University of Southern
California.
The authors would like to acknowledge the members of the
Telomere Biology Core Lab at University of California San
Francisco, particularly Dr. Jue Lin, where the telomere assay
and initial quality control were completed.
Supplementary data
Supplementary data related to this article can be found at
https://doi.org/10.1016/j.trci.2019.11.003.References
[1] Blackburn EH. Structure and function of telomeres. Nature 1991;
350:569–73.
[2] Victorelli S, Passos JF. Telomeres and cell senescence - size matters
not. EBioMedicine 2017;21:14–20.
[3] Kimura M, Hjelmborg JV, Gardner JP, Bathum L, Brimacombe M,
Lu X, et al. Telomere length and mortality: a study of leukocytes in
elderly Danish twins. Am J Epidemiol 2008;167:799–806.
[4] Benetos A, OkudaK, LajemiM, KimuraM, Thomas F, Skurnick J, et al.
Telomere length as an indicator of biological aging: the gender effect and
relationwith pulse pressure and pulsewave velocity. Hypertension 2001;
37:381–5.
[5] Zekry D, Herrmann FR, Irminger-Finger I, Ortolan L, Genet C,
Vitale AM, et al. Telomere length is not predictive of dementia or
MCI conversion in the oldest old. Neurobiol Aging 2010;31:719–20.
[6] Takata Y, KikukawaM, Hanyu H, Koyama S, Shimizu S, Umahara T,
et al. Association between ApoE phenotypes and telomere erosion
in Alzheimer’s disease. J Gerontol A Biol Sci Med Sci 2012;
67:330–5.
[7] Thomas P, O’Callaghan NJ, FenechM. Telomere length in white blood
cells, buccal cells and brain tissue and its variation with ageing and
Alzheimer’s disease. Mech Ageing Dev 2008;129:183–90.
[8] Panossian LA, Porter VR, Valenzuela HF, Zhu X, Reback E,
MastermanD, et al. Telomere shortening in T cells correlates with Alz-
heimer’s disease status. Neurobiol Aging 2003;24:77–84.
[9] Forero DA, Gonzalez-Giraldo Y, Lopez-Quintero C, Castro-Vega LJ,
Barreto GE, Perry G. Meta-analysis of telomere length in Alzheimer’s
disease. J Gerontol A Biol Sci Med Sci 2016;71:1069–73.
[10] Franco S, Blasco MA, Siedlak SL, Harris PL, Moreira PI, Perry G, et al.
Telomeres and telomerase in Alzheimer’s disease: epiphenomena or a
new focus for therapeutic strategy? Alzheimers Dement 2006;2:164–8.
[11] Honig LS, Kang MS, Schupf N, Lee JH, Mayeux R. Association of
shorter leukocyte telomere repeat length with dementia and mortality.
Arch Neurol 2012;69:1332–9.
[12] Martin-Ruiz C, Dickinson HO, Keys B, Rowan E, Kenny RA, Von
Zglinicki T. Telomere length predicts poststroke mortality, dementia,
and cognitive decline. Ann Neurol 2006;60:174–80.
[13] Yaffe K, Lindquist K, KluseM, Cawthon R, Harris T, HsuehWC, et al.
Telomere length and cognitive function in community-dwelling
elders: findings from the Health ABC Study. Neurobiol Aging 2011;
32:2055–60.
[14] Devore EE, Prescott J, De Vivo I, Grodstein F. Relative telomere
length and cognitive decline in the Nurses’ Health Study. Neurosci
Lett 2011;492:15–8.
[15] Insel KC, Merkle CJ, Hsiao CP, Vidrine AN, Montgomery DW. Bio-
markers for cognitive aging part I: telomere length, blood pressure
and cognition among individuals with hypertension. Biol Res Nurs
2012;14:124–32.
[16] Mather KA, JormAF, Anstey KJ,Milburn PJ, Easteal S, ChristensenH.
Cognitive performance and leukocyte telomere length in two narrow
age-range cohorts: a population study. BMC Geriatr 2010;10:62.
[17] Roberts RO, Boardman LA, Cha RH, Pankratz VS, Johnson RA,
Druliner BR, et al. Short and long telomeres increase risk of amnestic
mild cognitive impairment. Mech Ageing Dev 2014;141-142:64–9.
[18] Moverare-Skrtic S, Johansson P, Mattsson N, Hansson O, Wallin A,
Johansson JO, et al. Leukocyte telomere length (LTL) is reduced in sta-
ble mild cognitive impairment but low LTL is not associated with con-
version to Alzheimer’s disease: a pilot study. Exp Gerontol 2012;
47:179–82.
[19] Hohman TJ, Koran MEI, Thornton-Wells TA, Alzheimer’s Neuroimag-
ing Initiative. Genetic variation modifies risk for neurodegeneration
based on biomarker status. Front Aging Neurosci 2014;6:183.
[20] Hohman TJ, Koran MI, Thornton-Wells TA. Genetic modification of
the relationship between phosphorylated tau and neurodegeneration.
Alzheimers Dement 2014;10:637–45.
E.R. Mahoney et al. / Alzheimer’s & Dementia: Translational Research & Clinical Interventions 5 (2019) 883-890890[21] Rolyan H, Scheffold A, Heinrich A, Begus-Nahrmann Y, Langkopf BH,
Holter SM, et al. Telomere shortening reduces Alzheimer’s disease
amyloid pathology in mice. Brain 2011;134:2044–56.
[22] WikgrenM, Karlsson T, Nilbrink T, Nordfjall K, Hultdin J, Sleegers K,
et al. APOE epsilon4 is associated with longer telomeres, and longer
telomeres among epsilon4 carriers predicts worse episodic memory.
Neurobiol Aging 2012;33:335–44.
[23] Nudelman KNH, Lin J, Lane KA, Nho K, Kim S, Faber KM, et al.
Telomere shortening in the Alzheimer’s disease neuroimaging initia-
tive cohort. J Alzheimers Dis 2019;71:33–43.
[24] Crane PK, Carle A, Gibbons LE, Insel P, Mackin RS, Gross A, et al.
Development and assessment of a composite score for memory in the
Alzheimer’s Disease Neuroimaging Initiative (ADNI). Brain Imaging
Behav 2012;6:502–16.
[25] Gibbons LE, Carle AC, Mackin RS, Harvey D, Mukherjee S, Insel P,
et al. A composite score for executive functioning, validated in Alz-
heimer’s Disease Neuroimaging Initiative (ADNI) participants with
baseline mild cognitive impairment. Brain Imaging Behav 2012;
6:517–27.
[26] Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS,
Petersen RC, et al. Cerebrospinal fluid biomarker signature in Alz-
heimer’s disease neuroimaging initiative subjects. Ann Neurol 2009;
65:403–13.
[27] Jagust WJ, Landau SM, Shaw LM, Trojanowski JQ, Koeppe RA,
Reiman EM, et al. Relationships between biomarkers in aging and de-
mentia. Neurology 2009;73:1193–9.
[28] Jack CR, Bernstein MA, Fox NC, Thompson P, Alexander G,
Harvey D, et al. The Alzheimer’s disease neuroimaging initiative
(ADNI): MRI methods. J Magn Reson Imaging 2008;27:685–91.
[29] Hohman TJ, Tommet D, Marks S, Contreras J, Jones R, Mungas D.
Evaluating Alzheimer disease biomarkers as mediators of age-
related cognitive decline. Neurobiol Aging 2017;58:120–8.
[30] Carmichael O, McLaren DG, Tommet D, Mungas D, Jones RN.
Coevolution of brain structures in amnestic mild cognitive impair-
ment. Neuroimage 2013;66:449–56.
[31] Cai Z, Yan LJ, Ratka A. Telomere shortening and Alzheimer’s disease.
Neuromolecular Med 2013;15:25–48.
[32] Liu M, Huo YR, Wang J, Wang C, Liu S, Liu S, et al. Telomere short-
ening in Alzheimer’s disease patients. Ann Clin Lab Sci 2016;
46:260–5.
[33] Gizard F, Heywood EB, Findeisen HM, Zhao Y, Jones KL, Cudejko C,
et al. Telomerase activation in atherosclerosis and induction of telome-
rase reverse transcriptase expression by inflammatory stimuli in mac-
rophages. Arterioscler Thromb Vasc Biol 2011;31:245–52.
[34] Weng NP, Levine BL, June CH, Hodes RJ. Regulated expression of
telomerase activity in human T lymphocyte development and activa-
tion. J Exp Med 1996;183:2471–9.[35] Hathcock KS, Weng NP, Merica R, Jenkins MK, Hodes R. Cutting
edge: antigen-dependent regulation of telomerase activity in murine
T cells. J Immunol 1998;160:5702–6.
[36] Wang MM, Miao D, Cao XP, Tan L, Tan L. Innate immune activation
in Alzheimer’s disease. Ann Transl Med 2018;6:177.
[37] Wang J, Zhao C, Zhao A, Li M, Ren J, Qu X. New insights in amyloid
beta interactions with human telomerase. J Am Chem Soc 2015;
137:1213–9.
[38] LaFerla FM, Green KN, Oddo S. Intracellular amyloid-beta in Alz-
heimer’s disease. Nat Rev Neurosci 2007;8:499–509.
[39] SpilsburyA,Miwa S, Attems J, Saretzki G. The role of telomerase pro-
tein TERT in Alzheimer’s disease and in tau-related pathology in vitro.
J Neurosci 2015;35:1659–74.
[40] Zhu H, Fu W, Mattson MP. The catalytic subunit of telomerase protects
neurons against amyloid beta-peptide-induced apoptosis. J Neurochem
2000;75:117–24.
[41] Jofre-Monseny L, Minihane A-M, Rimbach G. Impact of apoE geno-
type on oxidative stress, inflammation and disease risk. Mol Nutr Food
Res 2008;52:131–45.
[42] Hohman TJ, Dumitrescu L, Barnes LL, ThambisettyM, BeechamGW,
Kunkle B, et al. Sex-specific effects of Apolipoprotein E with cerebro-
spinal fluid levels of tau. JAMA Neurol 2018;75:989–98.
[43] King KS, Kozlitina J, Rosenberg RN, Peshock RM, McColl RW,
Garcia CK. Effect of leukocyte telomere length on total and regional
brain volumes in a large population-based cohort. JAMA Neurol
2014;71:1247–54.
[44] Wikgren M, Karlsson T, Soderlund H, Nordin A, Roos G, Nilsson LG,
et al. Shorter telomere length is linked to brain atrophy and white mat-
ter hyperintensities. Age Ageing 2014;43:212–7.
[45] Jacobs EG, Epel ES, Lin J, Blackburn EH, Rasgon NL. Relationship
between leukocyte telomere length, telomerase activity, and hippo-
campal volume in early aging. JAMA Neurol 2014;71:921–3.
[46] Jack CR Jr, Petersen RC, Xu YC, Waring SC, O’Brien PC,
Tangalos EG, et al. Medial temporal atrophy on MRI in normal aging
and very mild Alzheimer’s disease. Neurology 1997;49:786–94.
[47] Jack CR, Bennett DA, Blennow K, Carrillo MC, Feldman HH,
Frisoni GB, et al. A/T/N: an unbiased descriptive classification scheme
for Alzheimer disease biomarkers. Neurology 2016;87:539–47.
[48] Lukens JN, VanDeerlinV, ClarkCM,Xie SX, Johnson FB.Comparisons
of telomere lengths in peripheral blood and cerebellum in Alzheimer’s
disease. Alzheimers Dement 2009;5:463–9.
[49] Paul L. Diet, nutrition and telomere length. J Nutr Biochem 2011;
22:895–901.
[50] Shiels PG, McGlynn LM, MacIntyre A, Johnson PC, Batty GD,
Burns H, et al. Accelerated telomere attrition is associated with rela-
tive household income, diet and inflammation in the pSoBid cohort.
PLoS One 2011;6:e22521.
